PT  - JOURNAL ARTICLE
AU  - Sinclair, Heather Q.
ED  - Holman, Rury R.
TI  - Results from the NAVIGATOR Trial
DP  - 2010 May 01
TA  - MD Conference Express
PG  - 12--13
VI  - 10
IP  - 2
4099  - http://mdc.sagepub.com/content/10/2/12.2.short
4100  - http://mdc.sagepub.com/content/10/2/12.2.full
AB  - There is no evidence of cardiovascular benefit that is associated with long-term treatment with nateglinide and valsartan in patients with impaired glucose tolerance and cardiovascular disease (CVD) or CV risk factors. However, valsartan therapy is associated with a reduction in the incidence of diabetes. This article discusses results from the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research [NAVIGATOR; NCT00097786] Trial.